Investigational drug · Phase 2
ECI830
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ECI830"
First trial start
2025
Apr 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ECI830", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced HR+/HER2- Breast Cancer
- Advanced CCNE1-amplified Solid Tumors
- Extensive-stage Small Cell Lung Cancer
Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ECI830" as an intervention, largest first.
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06726148 · 280 participants (planned) · Start Apr 3, 2025 · Primary completion Sep 25, 2028
Drug: ECI830; ribociclib and 1 more · For: Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Extensive-stage Small Cell Lung Cancer
Sites: Los Angeles, California; Fort Myers, Florida; Boston, Massachusetts · 33 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced HR+/HER2- Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.